 Matthew Wicklund
Concepts (174)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Muscular Dystrophies, Limb-Girdle | 9 | 2023 | 12 | 3.070 |
Why?
| | Muscle Proteins | 6 | 2018 | 210 | 1.310 |
Why?
| | Myositis, Inclusion Body | 4 | 2023 | 11 | 1.040 |
Why?
| | Muscle, Skeletal | 7 | 2022 | 1468 | 0.810 |
Why?
| | Muscular Dystrophy, Duchenne | 5 | 2022 | 80 | 0.780 |
Why?
| | Amyotrophic Lateral Sclerosis | 3 | 2018 | 60 | 0.730 |
Why?
| | Muscular Dystrophies | 4 | 2014 | 36 | 0.730 |
Why?
| | Myasthenic Syndromes, Congenital | 1 | 2018 | 1 | 0.630 |
Why?
| | Environmental Exposure | 2 | 2011 | 372 | 0.480 |
Why?
| | Muscle Fibers, Skeletal | 1 | 2016 | 185 | 0.470 |
Why?
| | Prednisone | 4 | 2022 | 229 | 0.390 |
Why?
| | Membrane Proteins | 3 | 2014 | 1016 | 0.360 |
Why?
| | Muscular Diseases | 2 | 2023 | 104 | 0.340 |
Why?
| | Immunosuppressive Agents | 3 | 2019 | 641 | 0.330 |
Why?
| | Mutation, Missense | 2 | 2018 | 294 | 0.270 |
Why?
| | Middle Aged | 16 | 2021 | 26605 | 0.230 |
Why?
| | Humans | 33 | 2023 | 114045 | 0.230 |
Why?
| | Adult | 16 | 2023 | 30375 | 0.220 |
Why?
| | Proteostasis Deficiencies | 1 | 2023 | 6 | 0.210 |
Why?
| | Valosin Containing Protein | 2 | 2023 | 6 | 0.210 |
Why?
| | Male | 20 | 2023 | 55396 | 0.210 |
Why?
| | Muscular Dystrophy, Facioscapulohumeral | 1 | 2022 | 15 | 0.200 |
Why?
| | Pregnenediones | 2 | 2022 | 21 | 0.190 |
Why?
| | Dystrophin | 2 | 2020 | 30 | 0.190 |
Why?
| | Nortriptyline | 1 | 2021 | 5 | 0.180 |
Why?
| | Duloxetine Hydrochloride | 1 | 2021 | 8 | 0.180 |
Why?
| | Rare Diseases | 2 | 2019 | 88 | 0.180 |
Why?
| | Polyneuropathies | 1 | 2021 | 50 | 0.180 |
Why?
| | Cytomegalovirus Infections | 1 | 2022 | 180 | 0.170 |
Why?
| | Disease Progression | 3 | 2023 | 2371 | 0.170 |
Why?
| | Braces | 1 | 2019 | 22 | 0.170 |
Why?
| | Social Participation | 1 | 2019 | 13 | 0.170 |
Why?
| | Biopsy | 3 | 2019 | 1024 | 0.160 |
Why?
| | Analgesics | 1 | 2021 | 156 | 0.160 |
Why?
| | Ankle | 1 | 2019 | 70 | 0.160 |
Why?
| | Mobility Limitation | 1 | 2019 | 60 | 0.160 |
Why?
| | Oxidoreductases | 1 | 2019 | 89 | 0.160 |
Why?
| | Pyridostigmine Bromide | 1 | 2018 | 4 | 0.160 |
Why?
| | Myositis | 1 | 2019 | 44 | 0.160 |
Why?
| | Neuronal Outgrowth | 1 | 2018 | 10 | 0.160 |
Why?
| | Cholinesterase Inhibitors | 1 | 2018 | 24 | 0.150 |
Why?
| | Receptor, IGF Type 1 | 1 | 2018 | 58 | 0.150 |
Why?
| | Charcot-Marie-Tooth Disease | 1 | 2018 | 19 | 0.150 |
Why?
| | Osteitis Deformans | 1 | 2018 | 5 | 0.150 |
Why?
| | Female | 15 | 2023 | 59324 | 0.150 |
Why?
| | Dysferlin | 3 | 2014 | 6 | 0.150 |
Why?
| | Headache Disorders | 1 | 2018 | 12 | 0.150 |
Why?
| | Homozygote | 1 | 2018 | 187 | 0.150 |
Why?
| | Pain Management | 1 | 2021 | 285 | 0.150 |
Why?
| | Aged | 11 | 2021 | 18969 | 0.150 |
Why?
| | Mutation | 3 | 2018 | 3338 | 0.150 |
Why?
| | Glucocorticoids | 1 | 2022 | 526 | 0.150 |
Why?
| | Propofol | 1 | 2018 | 43 | 0.140 |
Why?
| | Steroids | 1 | 2018 | 143 | 0.140 |
Why?
| | Checklist | 1 | 2018 | 84 | 0.140 |
Why?
| | Phenotype | 6 | 2023 | 2784 | 0.140 |
Why?
| | Multicenter Studies as Topic | 1 | 2018 | 249 | 0.140 |
Why?
| | Parkinson Disease | 2 | 2019 | 345 | 0.140 |
Why?
| | Hypnotics and Sedatives | 1 | 2018 | 133 | 0.140 |
Why?
| | Activities of Daily Living | 1 | 2019 | 348 | 0.130 |
Why?
| | Myoglobinuria | 1 | 2016 | 2 | 0.130 |
Why?
| | Myasthenia Gravis | 1 | 2016 | 18 | 0.130 |
Why?
| | Complement Membrane Attack Complex | 1 | 2016 | 33 | 0.130 |
Why?
| | Autoimmune Diseases | 1 | 2019 | 381 | 0.130 |
Why?
| | Young Adult | 7 | 2021 | 10444 | 0.130 |
Why?
| | Staining and Labeling | 1 | 2016 | 134 | 0.130 |
Why?
| | Endoscopy | 1 | 2018 | 245 | 0.130 |
Why?
| | Glycogen Storage Disease Type II | 1 | 2015 | 7 | 0.120 |
Why?
| | Research Design | 2 | 2018 | 919 | 0.120 |
Why?
| | Immunoglobulin G | 1 | 2019 | 766 | 0.120 |
Why?
| | Double-Blind Method | 4 | 2023 | 1656 | 0.120 |
Why?
| | Methotrexate | 1 | 2016 | 227 | 0.120 |
Why?
| | Nuclear Proteins | 1 | 2019 | 591 | 0.120 |
Why?
| | Adolescent | 9 | 2022 | 17800 | 0.120 |
Why?
| | Age of Onset | 2 | 2014 | 444 | 0.120 |
Why?
| | Autoantibodies | 2 | 2019 | 1347 | 0.120 |
Why?
| | Quadriceps Muscle | 1 | 2015 | 104 | 0.110 |
Why?
| | Lung Diseases, Interstitial | 1 | 2019 | 495 | 0.110 |
Why?
| | Clinical Trials as Topic | 1 | 2018 | 926 | 0.110 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2018 | 801 | 0.110 |
Why?
| | Quality of Life | 1 | 2021 | 2343 | 0.090 |
Why?
| | Genotype | 2 | 2006 | 1757 | 0.080 |
Why?
| | Athletic Injuries | 1 | 2016 | 456 | 0.080 |
Why?
| | Environment | 1 | 2011 | 333 | 0.080 |
Why?
| | Spinal Muscular Atrophies of Childhood | 1 | 2009 | 14 | 0.080 |
Why?
| | Dura Mater | 1 | 2009 | 27 | 0.080 |
Why?
| | Child | 6 | 2022 | 18401 | 0.080 |
Why?
| | Arm | 1 | 2009 | 104 | 0.080 |
Why?
| | Treatment Outcome | 5 | 2021 | 9049 | 0.080 |
Why?
| | Child, Preschool | 5 | 2022 | 9114 | 0.070 |
Why?
| | Spinal Cord | 1 | 2009 | 344 | 0.070 |
Why?
| | Range of Motion, Articular | 2 | 2019 | 350 | 0.070 |
Why?
| | Aged, 80 and over | 4 | 2021 | 6306 | 0.060 |
Why?
| | Exercise | 1 | 2016 | 1642 | 0.060 |
Why?
| | Signal Transduction | 1 | 2018 | 4501 | 0.060 |
Why?
| | Muscle Strength | 2 | 2019 | 271 | 0.060 |
Why?
| | Infant | 1 | 2018 | 7943 | 0.060 |
Why?
| | Prospective Studies | 3 | 2020 | 6195 | 0.060 |
Why?
| | Pentosyltransferases | 1 | 2003 | 3 | 0.050 |
Why?
| | Genes, Dominant | 1 | 2003 | 93 | 0.050 |
Why?
| | Genes, Recessive | 1 | 2003 | 74 | 0.050 |
Why?
| | Dystroglycans | 2 | 2016 | 7 | 0.050 |
Why?
| | Leg | 1 | 2003 | 224 | 0.050 |
Why?
| | Pregabalin | 1 | 2021 | 9 | 0.050 |
Why?
| | Mexiletine | 1 | 2021 | 7 | 0.050 |
Why?
| | Muscle Weakness | 1 | 2021 | 81 | 0.050 |
Why?
| | Comparative Effectiveness Research | 1 | 2021 | 131 | 0.040 |
Why?
| | Orthotic Devices | 1 | 2019 | 28 | 0.040 |
Why?
| | Stiff-Person Syndrome | 1 | 2019 | 7 | 0.040 |
Why?
| | Patient Reported Outcome Measures | 1 | 2021 | 251 | 0.040 |
Why?
| | Role | 1 | 2019 | 32 | 0.040 |
Why?
| | Symptom Assessment | 1 | 2020 | 119 | 0.040 |
Why?
| | Muscle Contraction | 1 | 2022 | 388 | 0.040 |
Why?
| | Neuralgia | 1 | 2021 | 122 | 0.040 |
Why?
| | Bayes Theorem | 1 | 2021 | 327 | 0.040 |
Why?
| | Pilot Projects | 1 | 2023 | 1360 | 0.040 |
Why?
| | Mycophenolic Acid | 1 | 2019 | 76 | 0.040 |
Why?
| | Biopsy, Needle | 1 | 2019 | 180 | 0.040 |
Why?
| | Foot | 1 | 2019 | 103 | 0.040 |
Why?
| | Glutamate Decarboxylase | 1 | 2019 | 160 | 0.040 |
Why?
| | Magnetic Resonance Imaging | 3 | 2022 | 3039 | 0.040 |
Why?
| | Gene Deletion | 1 | 2020 | 356 | 0.040 |
Why?
| | Syndrome | 1 | 2019 | 330 | 0.040 |
Why?
| | Contracts | 1 | 2018 | 9 | 0.040 |
Why?
| | Budgets | 1 | 2018 | 14 | 0.040 |
Why?
| | Mice, Inbred ICR | 1 | 2018 | 108 | 0.040 |
Why?
| | Surveys and Questionnaires | 2 | 2021 | 4595 | 0.040 |
Why?
| | Ankle Joint | 1 | 2019 | 152 | 0.040 |
Why?
| | Respiratory Function Tests | 1 | 2019 | 522 | 0.040 |
Why?
| | International Cooperation | 1 | 2018 | 169 | 0.040 |
Why?
| | Animals | 3 | 2023 | 31565 | 0.040 |
Why?
| | Research Support as Topic | 1 | 2018 | 107 | 0.040 |
Why?
| | Proteins | 1 | 2003 | 906 | 0.040 |
Why?
| | Heart Function Tests | 1 | 2017 | 60 | 0.030 |
Why?
| | Pedigree | 1 | 2018 | 460 | 0.030 |
Why?
| | Protein Transport | 1 | 2018 | 391 | 0.030 |
Why?
| | United States | 3 | 2023 | 12137 | 0.030 |
Why?
| | Physical Therapy Modalities | 1 | 2019 | 265 | 0.030 |
Why?
| | Vital Capacity | 1 | 2017 | 254 | 0.030 |
Why?
| | Receptors, Cholinergic | 1 | 2016 | 41 | 0.030 |
Why?
| | Walking | 1 | 2019 | 422 | 0.030 |
Why?
| | Patient Compliance | 1 | 2019 | 524 | 0.030 |
Why?
| | Area Under Curve | 1 | 2016 | 273 | 0.030 |
Why?
| | Recovery of Function | 1 | 2019 | 573 | 0.030 |
Why?
| | Disability Evaluation | 1 | 2017 | 271 | 0.030 |
Why?
| | Mice | 2 | 2023 | 14843 | 0.030 |
Why?
| | Canada | 1 | 2016 | 320 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2019 | 1624 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2017 | 714 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2019 | 1690 | 0.030 |
Why?
| | Qualitative Research | 1 | 2019 | 919 | 0.030 |
Why?
| | Patient Selection | 1 | 2018 | 629 | 0.030 |
Why?
| | Registries | 1 | 2021 | 1764 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2020 | 2384 | 0.030 |
Why?
| | Patient Satisfaction | 1 | 2017 | 571 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2018 | 2562 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2019 | 4392 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2014 | 1331 | 0.020 |
Why?
| | Evidence-Based Medicine | 1 | 2014 | 662 | 0.020 |
Why?
| | Risk Assessment | 1 | 2019 | 2958 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2019 | 2272 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2018 | 2090 | 0.020 |
Why?
| | Spinal Cord Compression | 1 | 2009 | 17 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2016 | 2537 | 0.020 |
Why?
| | Time Factors | 1 | 2018 | 6077 | 0.020 |
Why?
| | Magnetic Resonance Angiography | 1 | 2009 | 221 | 0.020 |
Why?
| | Radiography | 1 | 2009 | 803 | 0.020 |
Why?
| | Caveolin 1 | 1 | 2006 | 20 | 0.020 |
Why?
| | Calpain | 1 | 2006 | 53 | 0.020 |
Why?
| | Immunophenotyping | 1 | 2006 | 274 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 2006 | 373 | 0.020 |
Why?
| | Blotting, Western | 1 | 2006 | 1143 | 0.010 |
Why?
| | Creatine Kinase | 1 | 2003 | 75 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2019 | 12521 | 0.010 |
Why?
|
|
Wicklund's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|